These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30938215)

  • 21. Quantification and biodistribution of iron oxide nanoparticles in the primary clearance organs of mice using T
    Zhang J; Ring HL; Hurley KR; Shao Q; Carlson CS; Idiyatullin D; Manuchehrabadi N; Hoopes PJ; Haynes CL; Bischof JC; Garwood M
    Magn Reson Med; 2017 Aug; 78(2):702-712. PubMed ID: 27667655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fabrication of contrast agents for magnetic resonance imaging from polymer-brush-afforded iron oxide magnetic nanoparticles prepared by surface-initiated living radical polymerization.
    Ohno K; Mori C; Akashi T; Yoshida S; Tago Y; Tsujii Y; Tabata Y
    Biomacromolecules; 2013 Oct; 14(10):3453-62. PubMed ID: 23957585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.
    Zhou H; Qian W; Uckun FM; Wang L; Wang YA; Chen H; Kooby D; Yu Q; Lipowska M; Staley CA; Mao H; Yang L
    ACS Nano; 2015 Aug; 9(8):7976-91. PubMed ID: 26242412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stimuli-controllable iron oxide nanoparticle assemblies: Design, manipulation and bio-applications.
    Low LE; Lim HP; Ong YS; Siva SP; Sia CS; Goh BH; Chan ES; Tey BT
    J Control Release; 2022 May; 345():231-274. PubMed ID: 35306119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment.
    Alexiou C; Jurgons R; Schmid RJ; Bergemann C; Henke J; Erhardt W; Huenges E; Parak F
    J Drug Target; 2003 Apr; 11(3):139-49. PubMed ID: 13129824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of poly-l-lysine-modified iron oxide nanoparticles uptake into cells.
    Li Z; Shuai C; Li X; Li X; Xiang J; Li G
    J Biomed Mater Res A; 2013 Oct; 101(10):2846-50. PubMed ID: 23504952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intrinsically green iron oxide nanoparticles? From synthesis via (eco-)toxicology to scenario modelling.
    Filser J; Arndt D; Baumann J; Geppert M; Hackmann S; Luther EM; Pade C; Prenzel K; Wigger H; Arning J; Hohnholt MC; Köser J; Kück A; Lesnikov E; Neumann J; Schütrumpf S; Warrelmann J; Bäumer M; Dringen R; von Gleich A; Swiderek P; Thöming J
    Nanoscale; 2013 Feb; 5(3):1034-46. PubMed ID: 23255050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia.
    Pedrazzoli P; Rosti G; Secondino S; Siena S
    Cancer; 2009 Mar; 115(6):1169-73. PubMed ID: 19152436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative histochemistry for macrophage biodistribution on mice liver and spleen after the administration of a pharmacological-relevant dose of polyacrylic acid-coated iron oxide nanoparticles.
    Rodrigues D; Freitas M; Marisa Costa V; Arturo Lopez-Quintela M; Rivas J; Freitas P; Carvalho F; Fernandes E; Silva P
    Nanotoxicology; 2017 Mar; 11(2):256-266. PubMed ID: 28166432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PEGylated fullerene/iron oxide nanocomposites for photodynamic therapy, targeted drug delivery and MR imaging.
    Shi J; Yu X; Wang L; Liu Y; Gao J; Zhang J; Ma R; Liu R; Zhang Z
    Biomaterials; 2013 Dec; 34(37):9666-77. PubMed ID: 24034498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-mediated targeting of iron oxide nanoparticles to the folate receptor alpha increases tumor cell association in vitro and in vivo.
    Ndong C; Toraya-Brown S; Kekalo K; Baker I; Gerngross TU; Fiering SN; Griswold KE
    Int J Nanomedicine; 2015; 10():2595-617. PubMed ID: 25878495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacokinetics, tissue distribution and magnetic resonance's response characterstics of folic acid-O-carboxymethyl chitosan ultrasmall superparamagnetic iron oxide nanoparticles in mice and rats].
    Gao WH; Liu ST; Fan CX; Qi LY; Chen ZL
    Yao Xue Xue Bao; 2011 Jul; 46(7):845-51. PubMed ID: 22010356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluorescent magnetic nanoparticles with specific targeting functions for combinded targeting, optical imaging and magnetic resonance imaging.
    Chen YC; Chang WH; Wang SJ; Hsieh WY
    J Biomater Sci Polym Ed; 2012; 23(15):1903-22. PubMed ID: 22024467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
    Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles.
    Cole AJ; David AE; Wang J; Galbán CJ; Yang VC
    Biomaterials; 2011 Sep; 32(26):6291-301. PubMed ID: 21684593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Iron supplementation in chronic kidney disease].
    Graczyk M; Dylewska M
    Wiad Lek; 2017; 70(6 pt 2):1215-1218. PubMed ID: 29533917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activatable fluorescence imaging of macrophages in atherosclerotic plaques using iron oxide nanoparticles conjugated with indocyanine green.
    Ikeda H; Ishii A; Sano K; Chihara H; Arai D; Abekura Y; Nishi H; Ono M; Saji H; Miyamoto S
    Atherosclerosis; 2018 Aug; 275():1-10. PubMed ID: 29852399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting a G-protein-coupled receptor overexpressed in endocrine tumors by magnetic nanoparticles to induce cell death.
    Sanchez C; El Hajj Diab D; Connord V; Clerc P; Meunier E; Pipy B; Payré B; Tan RP; Gougeon M; Carrey J; Gigoux V; Fourmy D
    ACS Nano; 2014 Feb; 8(2):1350-63. PubMed ID: 24401079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease.
    Kowalczyk M; Banach M; Rysz J
    J Nephrol; 2011; 24(6):717-22. PubMed ID: 21956770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation.
    Pai AB
    Ann N Y Acad Sci; 2017 Nov; 1407(1):17-25. PubMed ID: 29027212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.